University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: Unexpected cardiac toxicity

Journal of Clinical Oncology

Volumn 19, Issue 18, 2001, Pages 3903-3904

  Gralow, J R ^a   Livingston, R B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; TRASTUZUMAB;

BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; SOUTH AFRICA; THROMBOCYTOPENIA;

EID: 0035884431     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.18.3903     Document Type: Letter

References (5)

1. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
2. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer
3. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study
4. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications
5. Intensive single-agent mitoxantrone fo metastatic breast cancer